// App-Quantinova.ai

11509 : Crizotinib in Children and Adolescents with Advanced ROS1, MET, or ALK-Rearranged Cancer: Results of the AcSe Phase II Trial

Researchers

Presenter

  • Gilles Vassal

Principal Investigators

  • Laura Faivre

  • Birgit Geoerger

  • Dominique Plantaz

  • Anne Auvrignon

  • Carole Coze

  • Nathalie Aladjidi

  • Arnauld Verschuur

  • Celine Icher

  • Minckes Odile

  • Nicolas Sirvent

  • Gudrun Schleiermacher

  • Nathalie Auger

  • Etienne Lonchamp

  • Celine Mahier - Ait Oukhatar

  • Marie-Cecile Le Deley

  • Marta Jimenez

  • Natalie Hoog Labouret

Medical Centers

  • Gustave Roussy, Villejuif, France

  • Hospital Pediatric Hematology, Grenoble, France

  • Pediatric Hematology, AP-HP, GH HUEP, Trousseau Hospital, Paris, France

  • Hopital d'Enfants de La Timone, Department of Pediatric Oncology, Marseille, France

  • CHU Bordeaux - Hopital Pellegrin, Bordeaux, France

  • Hopital des Enfants, Bordeaux, France

  • Hopital Cote De Nacre, Caen, France

  • CHU de Montpellier, Montpellier, France

  • Institut Curie, Paris Cedex, France

  • Gustave Roussy, Universite Paris-Saclay, Department of Biostatistics and Epidemiology, Villejuif, France

  • Institut National du Cancer, Boulogne Billancourt, France

  • Unicancer, Paris, France

  • Department of Biostatistics and Epidemiology, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France

  • UNICANCER, Paris, France

  • French National Cancer Institute (INCa), Boulogne-Billancourt, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Proto-oncogene tyrosine-protein kinase ROS

Drug/Treatment

  • Crizotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02034981

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved